GeoVax Labs, Inc., a clinical-stage biotechnology company, is set to present at the Emerging Growth Conference on July 16, 2025, offering key updates on its vaccine and cancer therapy programs. The presentation, led by Chairman and CEO David Dodd, will focus on the company's GEO-MVA, GEO-CM04S1, and Gedeptin® programs, showcasing recent progress and upcoming milestones.
The GEO-MVA program, a next-generation vaccine for Mpox and smallpox, has received favorable Scientific Advice from the European Medicines Agency, marking a significant step forward in global health preparedness. Meanwhile, the GEO-CM04S1 COVID-19 vaccine is undergoing Phase 2 clinical trials, targeting immunocompromised individuals and healthy adults, aiming to fill gaps left by current vaccines. Additionally, Gedeptin®, a therapy for solid tumors, is preparing for a Phase 2 trial in head and neck cancer, representing a promising avenue in oncology treatment.
GeoVax's participation in the conference underscores the importance of its MVA platform and U.S.-based manufacturing capabilities in addressing vaccine supply diversification and pandemic readiness. The event provides a platform for the investment community to engage with GeoVax's leadership and gain insights into the company's strategic direction and potential impact on public health and biosecurity.
